A Double-Blinded, Randomized, Dose-Comparison Pilot Study to Comparatively Evaluate Efficacy and Safety of Two Doses of Botulinum Toxin Type A Injection for Deltoid Muscle Hypertrophy.
Botulinum toxins
Deltoid muscle
Hypertrophy
Journal
Annals of dermatology
ISSN: 2005-3894
Titre abrégé: Ann Dermatol
Pays: Korea (South)
ID NLM: 8916577
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
28
07
2022
revised:
25
04
2023
accepted:
10
05
2023
medline:
13
10
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
ppublish
Résumé
Botulinum toxin type A (BTX-A) injection is being widely used off-label for muscular hypertrophy, including deltoid muscle hypertrophy. However, very few studies have evaluated the optimal dosage and its clinical response. This study aimed to assess the efficacy and safety of different doses of Prabotulinum toxin A (PBoNT) for treating deltoid muscle hypertrophy. Twelve particiapants with bilateral deltoid muscle hypertrophy were enrolled and randomly received either 16 U or 32 U of PBoNT. In each participant, the same dose was administered to both deltoid muscles. Both participants and evaluators were blinded. Deltoid muscle thickness and upper arm circumference were measured on day 0, and weeks 2, 4, and 12 after the PBoNT injection. Upper arm circumference significantly decreased in both groups; however, deltoid muscle thickness was reduced in the 16 U group only. No major complications were reported in both groups. However, a few minor complications were reported in the 16 U injection group. Both 16 U and 32 U of PBoNT intramuscular injections are safe and effective in treating deltoid hypertrophy.
Sections du résumé
BACKGROUND
BACKGROUND
Botulinum toxin type A (BTX-A) injection is being widely used off-label for muscular hypertrophy, including deltoid muscle hypertrophy. However, very few studies have evaluated the optimal dosage and its clinical response.
OBJECTIVE
OBJECTIVE
This study aimed to assess the efficacy and safety of different doses of Prabotulinum toxin A (PBoNT) for treating deltoid muscle hypertrophy.
METHODS
METHODS
Twelve particiapants with bilateral deltoid muscle hypertrophy were enrolled and randomly received either 16 U or 32 U of PBoNT. In each participant, the same dose was administered to both deltoid muscles. Both participants and evaluators were blinded. Deltoid muscle thickness and upper arm circumference were measured on day 0, and weeks 2, 4, and 12 after the PBoNT injection.
RESULTS
RESULTS
Upper arm circumference significantly decreased in both groups; however, deltoid muscle thickness was reduced in the 16 U group only. No major complications were reported in both groups. However, a few minor complications were reported in the 16 U injection group.
CONCLUSION
CONCLUSIONS
Both 16 U and 32 U of PBoNT intramuscular injections are safe and effective in treating deltoid hypertrophy.
Identifiants
pubmed: 37830417
pii: 35.355
doi: 10.5021/ad.22.155
pmc: PMC10579568
doi:
Types de publication
Journal Article
Langues
eng
Pagination
355-359Informations de copyright
Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology.
Déclaration de conflit d'intérêts
K.Y. Park and W.W. Choi are consultants and speakers of Deawoong Pharmaceuticals Inc., Korea.
Références
J Cosmet Dermatol. 2020 Nov;19(11):2785-2804
pubmed: 32866999
J Eur Acad Dermatol Venereol. 2017 Jan;31(1):e46-e47
pubmed: 27615707
Dermatol Ther. 2021 Nov;34(6):e15168
pubmed: 34676643
Plast Reconstr Surg. 2007 Feb;119(2):711-7
pubmed: 17230111
Aesthet Surg J. 2018 Jul 13;38(8):850-860
pubmed: 29546270
J Clin Ultrasound. 2001 May;29(4):230-6
pubmed: 11323778
J Dermatolog Treat. 2006;17(4):250-4
pubmed: 16971324
Arch Craniofac Surg. 2021 Feb;22(1):1-10
pubmed: 33714246
Dermatol Surg. 2004 Jun;30(6):867-71; discussion 871
pubmed: 15171764
J Craniomaxillofac Surg. 2022 Jan;50(1):7-18
pubmed: 34620536
Aesthet Surg J. 2016 Apr;36(4):482-7
pubmed: 26780946
Aesthetic Plast Surg. 2018 Dec;42(6):1664-1671
pubmed: 30206648
Aesthet Surg J. 2017 Oct 16;37(10):1146-1156
pubmed: 29040400